Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - Cantor Fitzgerald has maintained its Overweight rating and $13.00 price target on Taysha Gene Therapies (NASDAQ:TSHA), which has demonstrated remarkable performance with a 310% return over the past six months. According to InvestingPro data, analysts’ targets range from $5 to $14, with a strong consensus recommendation of 1.25 (Strong Buy).
The research firm believes Taysha Gene Therapies remains significantly undervalued in the current market, regardless of which entity ultimately commercializes its product.
Cantor Fitzgerald notes that Taysha is well-capitalized and possesses the expertise necessary to bring its product to market independently.
The firm points to a significant valuation discrepancy, highlighting that Taysha currently trades at approximately one-third of uniQure’s (NASDAQ:QURE) market capitalization, despite similarities between the companies.
Both companies have late-stage de-risking data and regulatory support, with Cantor estimating that uniQure’s initial market potential could reach approximately 5,000-6,000 U.S. patients compared to about 10,000 U.S. patients for Taysha.
In other recent news, Taysha Gene Therapies announced it has regained full rights to its TSHA-102 program for Rett syndrome after the expiration of a previous option agreement with Astellas. This development gives Taysha unencumbered control over its gene therapy program. The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Taysha’s TSHA-102, following clinical evidence showing promising results in the REVEAL Phase 1/2 trials. This designation is intended to support the planned Biologics License Application submission. Additionally, Taysha has finalized regulatory alignment with the FDA on the pivotal trial protocol and statistical analysis plan for TSHA-102. Analyst firm Citizens reiterated a Market Outperform rating for Taysha, citing the company’s potential in treating Rett syndrome. Meanwhile, Baird raised its price target for Taysha’s stock from $7.00 to $12.00, maintaining an Outperform rating. These developments highlight the company’s progress and potential in advancing its gene therapy treatment for Rett syndrome.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.